CEBPA-DT

Summary

CEBPA-DT (CEBPA divergent transcript, HGNC:25710) is a long non-coding RNA gene on chromosome 19q13.11.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25710
Approved symbol	CEBPA-DT
Name	CEBPA divergent transcript
Location	19q13.11
Locus type	RNA, long non-coding
Status	Approved
Aliases	ADINR
Ensembl gene	ENSG00000267296
Ensembl biotype	lncRNA
OMIM	620560
Entrez	80054
RNAcentral	URS0000CCE086 — lncRNA, 2252 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 lncRNA

ENST00000592982, ENST00000718467, ENST00000718468, ENST00000718469, ENST00000718470, ENST00000718471, ENST00000718472

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000592982 — 1 exons

Exon	Start	End
ENSE00004035185	33302857	33305057

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 86.29.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6955 / max 10.5370, expressed in 418 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
208773	0.6955	418

Top tissues by expression

130 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.29	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.85	gold quality
mucosa of transverse colon	UBERON:0004991	79.07	gold quality
right uterine tube	UBERON:0001302	74.98	gold quality
duodenum	UBERON:0002114	73.45	gold quality
gastrocnemius	UBERON:0001388	73.07	gold quality
muscle of leg	UBERON:0001383	72.48	gold quality
monocyte	CL:0000576	72.45	gold quality
leukocyte	CL:0000738	72.23	gold quality
hindlimb stylopod muscle	UBERON:0004252	71.79	gold quality
skeletal muscle tissue	UBERON:0001134	71.61	gold quality
right lobe of liver	UBERON:0001114	71.27	gold quality
liver	UBERON:0002107	70.69	gold quality
putamen	UBERON:0001874	69.58	gold quality
caudate nucleus	UBERON:0001873	69.16	gold quality
transverse colon	UBERON:0001157	69.07	gold quality
nucleus accumbens	UBERON:0001882	68.99	gold quality
colonic epithelium	UBERON:0000397	68.83	silver quality
muscle tissue	UBERON:0002385	68.77	gold quality
skin of abdomen	UBERON:0001416	68.03	gold quality
fundus of stomach	UBERON:0001160	67.93	gold quality
body of uterus	UBERON:0009853	67.89	gold quality
subcutaneous adipose tissue	UBERON:0002190	67.66	gold quality
right lobe of thyroid gland	UBERON:0001119	67.48	gold quality
fallopian tube	UBERON:0003889	67.29	gold quality
adipose tissue	UBERON:0001013	67.27	gold quality
ectocervix	UBERON:0012249	67.06	gold quality
prefrontal cortex	UBERON:0000451	67.05	gold quality
thyroid gland	UBERON:0002046	66.99	gold quality
thoracic mammary gland	UBERON:0005200	66.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.42

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 4)

• Study results clarify that CEBPA-AS1 up-regulated in oral squamous cell carcinoma (OSCC), correlated with poor differentiation, lymph node metastasis and high clinical stage, could be a prognostic biomarker of OSCC patients. (PMID:29281558)
• Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer. (PMID:34790046)
• LncRNA CEBPA-AS1 knockdown prevents neuronal apoptosis against oxygen glucose deprivation/reoxygenation by regulating the miR-455/GPER1 axis. (PMID:35088289)
• ZFX-mediated upregulation of CEBPA-AS1 contributes to acute myeloid leukemia progression through miR-24-3p/CTBP2 axis. (PMID:36715854)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.